China seems to have increased price of Key Starting Raw material by 20% for our API makers… So if any of our API maker is dependent upon china only for the raw material , then the bottom line could be hit to the extent of its Chinese import content. The API maker may not be hit , if it has a second source either from india or some other country at a reasonable/ competitive price !
Similarly, China has hiked its API price by 20% and so our Generic pharma makers those who depend upon China only for its API could also be hit to the extent it imports from China!